- Home
- GSBC vs CGEM Comparison
GSBC vs CGEM Comparison
Compare GSBC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- CGEM
- Stock Information
- Founded
- GSBC 1923
- CGEM 2016
- Country
- GSBC United States
- CGEM United States
- Employees
- GSBC N/A
- CGEM N/A
- Industry
- GSBC Major Banks
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- GSBC Finance
- CGEM Health Care
- Exchange
- GSBC Nasdaq
- CGEM Nasdaq
- Market Cap
- GSBC 769.0M
- CGEM 730.2M
- IPO Year
- GSBC N/A
- CGEM 2021
- Fundamental
- Price
- GSBC $60.34
- CGEM $12.05
- Analyst Decision
- GSBC Hold
- CGEM Strong Buy
- Analyst Count
- GSBC 2
- CGEM 7
- Target Price
- GSBC $60.00
- CGEM $31.67
- AVG Volume (30 Days)
- GSBC 32.9K
- CGEM 521.0K
- Earning Date
- GSBC 01-21-2025
- CGEM 11-07-2024
- Dividend Yield
- GSBC 2.61%
- CGEM N/A
- EPS Growth
- GSBC N/A
- CGEM N/A
- EPS
- GSBC 5.07
- CGEM N/A
- Revenue
- GSBC $214,729,000.00
- CGEM N/A
- Revenue This Year
- GSBC N/A
- CGEM N/A
- Revenue Next Year
- GSBC $4.21
- CGEM N/A
- P/E Ratio
- GSBC $12.08
- CGEM N/A
- Revenue Growth
- GSBC N/A
- CGEM N/A
- 52 Week Low
- GSBC $48.19
- CGEM $9.91
- 52 Week High
- GSBC $68.02
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- GSBC 44.04
- CGEM 49.82
- Support Level
- GSBC $60.00
- CGEM $10.44
- Resistance Level
- GSBC $66.85
- CGEM $12.95
- Average True Range (ATR)
- GSBC 1.97
- CGEM 0.68
- MACD
- GSBC -0.61
- CGEM 0.22
- Stochastic Oscillator
- GSBC 27.85
- CGEM 71.52
About GSBC Great Southern Bancorp Inc.
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.